AACC biennial activity report

All JCTLM Members are invited to attend the Members’ and Stakeholders’ Meeting, which is held once every two years, and submit a report of their activities in support of traceability in laboratory medicine over the preceding period.

For that purpose this template document provides guidance to JCTLM Members for drafting their biennial activity report. Organizations are invited to provide the information below for submission to the Executive Committee.

<table>
<thead>
<tr>
<th>Organization Name:</th>
<th>American Association for Clinical Chemistry</th>
</tr>
</thead>
<tbody>
<tr>
<td>JCTLM Member status:</td>
<td>National and Regional Member</td>
</tr>
<tr>
<td>Author(s):</td>
<td>Loretta Doan, PhD</td>
</tr>
<tr>
<td>Author(s) email(s):</td>
<td><a href="mailto:ldoan@aacc.org">ldoan@aacc.org</a></td>
</tr>
<tr>
<td>Period covered:</td>
<td>2020 – 2021</td>
</tr>
</tbody>
</table>

1. Major achievement(s) in support of standardization in laboratory medicine
AACC and its allies in the healthcare community succeeded in getting federal funding for the Centers for Disease Control and Prevention to expand its harmonization activities in fiscal years (FY) 2018, 2019, 2020, 2021, and it appears 2022. While the new Biden Administration did not address harmonization funding in its FY2022 proposal, the association is hopeful that it may be addressed in the FY2023 budget. AACC will continue to work with its partners to garner congressional support for an increase in funding harmonization efforts.

CDC in an update to Congress on its harmonization efforts stated the following:

In FY 2018 and FY 2019, CDC received additional funding to improve the quality and reliability of diagnostic tests for hormones. With this funding, CDC is expanding its pilot hormone harmonization program to include new biomarkers and reach more manufacturers, hospital laboratories, and commercial laboratories. CDC added a new accuracy-based monitoring service that tracks measurement accuracy for clinical laboratories and also developed two new reference methods for measuring total and free thyroxine, a necessary and important first step in improving the accuracy and reliability of thyroid function tests. CDC expects these efforts to produce substantial cost savings in clinical care and reduce incorrect diagnosis and treatment of thyroid disease.

In FY 2021, CDC will begin to harmonize three new clinical tests by developing or improving reference methods for priority chronic disease biomarkers such as parathyroid hormones and creatinine and by assigning target levels to reference materials for thyroid and other hormones. CDC will further expand the reach of ongoing harmonization programs to additional laboratories and manufacturers to harmonize results on high priority lab tests. These activities will improve the diagnosis, treatment, and prevention of chronic kidney diseases, diabetes, certain cancers, osteoporosis, developmental diseases (such as polycystic ovary syndrome) and thyroid diseases.

2. Planned activity(ies) in support of standardization in laboratory medicine
   See above.

3. Promoting traceability in laboratory medicine
See above.

4. Reference laboratory networks /collaborations focusing on developing /implementing reference measurement systems
   See above.

5. Open questions and suggestions to be addressed by JCTLM
   (Suggestions on issues related to standardization and metrological traceability that should be considered by the JCTLM)
   See above.

Note: The information of this report will be accessible publicly on the relevant JCTLM Members webpage, unless the author of the report states otherwise. In the case the organization does not authorize the publication of the report in part or full, the author will add a statement to clarify which part(s) of the report will/will not be rendered public.